DE69430611D1 - Phosphonooxymethyl oder Methylthiomethylether von Taxanderivaten als Antitumormittel - Google Patents

Phosphonooxymethyl oder Methylthiomethylether von Taxanderivaten als Antitumormittel

Info

Publication number
DE69430611D1
DE69430611D1 DE69430611T DE69430611T DE69430611D1 DE 69430611 D1 DE69430611 D1 DE 69430611D1 DE 69430611 T DE69430611 T DE 69430611T DE 69430611 T DE69430611 T DE 69430611T DE 69430611 D1 DE69430611 D1 DE 69430611D1
Authority
DE
Germany
Prior art keywords
phosphonooxymethyl
taxane derivatives
tumor agent
methylthiomethyl ether
methylthiomethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69430611T
Other languages
English (en)
Other versions
DE69430611T2 (de
Inventor
Jerzy Golik
John F Kadow
Murray A Kaplan
Wen-Sen Li
Robert K Perrone
John K Thottathil
Dolatrai Vyas
Mark D Wittman
Henry Wong
John J Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DE69430611D1 publication Critical patent/DE69430611D1/de
Publication of DE69430611T2 publication Critical patent/DE69430611T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6551—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
    • C07F9/65512—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/04—Manufacture or treatment of semiconductor devices or of parts thereof the devices having potential barriers, e.g. a PN junction, depletion layer or carrier concentration layer
    • H01L21/48—Manufacture or treatment of parts, e.g. containers, prior to assembly of the devices, using processes not provided for in a single one of the subgroups H01L21/06 - H01L21/326
    • H01L21/4814—Conductive parts
    • H01L21/4821—Flat leads, e.g. lead frames with or without insulating supports
    • H01L21/4839—Assembly of a flat lead with an insulating support, e.g. for TAB
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Computer Hardware Design (AREA)
  • Epidemiology (AREA)
  • Power Engineering (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69430611T 1993-08-17 1994-08-16 Phosphonooxymethyl oder Methylthiomethylether von Taxanderivaten als Antitumormittel Expired - Fee Related DE69430611T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10801593A 1993-08-17 1993-08-17
US15484093A 1993-11-24 1993-11-24
US24511994A 1994-05-17 1994-05-17

Publications (2)

Publication Number Publication Date
DE69430611D1 true DE69430611D1 (de) 2002-06-20
DE69430611T2 DE69430611T2 (de) 2002-12-19

Family

ID=27380403

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69430611T Expired - Fee Related DE69430611T2 (de) 1993-08-17 1994-08-16 Phosphonooxymethyl oder Methylthiomethylether von Taxanderivaten als Antitumormittel

Country Status (20)

Country Link
EP (1) EP0639577B1 (de)
JP (1) JP3062986B2 (de)
KR (1) KR100249306B1 (de)
CN (2) CN1051315C (de)
AT (1) ATE217629T1 (de)
AU (2) AU694941B2 (de)
CA (1) CA2129288C (de)
CY (1) CY2295B1 (de)
CZ (1) CZ194794A3 (de)
DE (1) DE69430611T2 (de)
DK (1) DK0639577T3 (de)
ES (1) ES2176212T3 (de)
FI (1) FI113271B (de)
HU (1) HUT67742A (de)
IL (2) IL110660A0 (de)
NO (1) NO309093B1 (de)
NZ (1) NZ264240A (de)
PL (1) PL179636B1 (de)
PT (1) PT639577E (de)
RU (1) RU2128661C1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
CA2111527C (en) * 1992-12-24 2000-07-18 Jerzy Golik Phosphonooxymethyl ethers of taxane derivatives
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
FR2732340B1 (fr) * 1995-03-27 1997-04-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US6232477B1 (en) 1996-03-25 2001-05-15 Aventis Pharma S.A. Methods of preparing new taxoids and pharmaceutical compositions containing them
US6593482B2 (en) 1993-02-01 2003-07-15 Aventis Pharma S.A. Methods for preparing new taxoids and pharmaceutical compositions containing them
US6040466A (en) * 1996-03-25 2000-03-21 Rhone Poulenc Rorer Sa Taxoids, their preparation and pharmaceutical compositions containing them
US5677470A (en) * 1994-06-28 1997-10-14 Tanabe Seiyaku Co., Ltd. Baccatin derivatives and processes for preparing the same
US6500858B2 (en) 1994-10-28 2002-12-31 The Research Foundation Of The State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
WO1996013495A1 (en) * 1994-10-28 1996-05-09 The Research Foundation Of State University Of New York Taxoid derivatives, their preparation and their use as antitumor agents
US6458976B1 (en) 1994-10-28 2002-10-01 The Research Foundation Of State University Of New York Taxoid anti-tumor agents, pharmaceutical compositions, and treatment methods
CA2162759A1 (en) * 1994-11-17 1996-05-18 Kenji Tsujihara Baccatin derivatives and processes for preparing the same
MA23823A1 (fr) * 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
US5847170A (en) * 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
US6372780B2 (en) 1995-03-27 2002-04-16 Aventis Pharma S.A. Methods of treating cell lines expressing multidrug resistance P-glycoprotein
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1997027855A1 (en) * 1996-01-31 1997-08-07 Bristol-Myers Squibb Company A method of making pharmaceutically active taxanes orally bioavailable
EP0975340B2 (de) 1997-03-31 2009-10-28 Boston Scientific Limited Verwendung von cytoskelettinhibitoren zur vorbeugung der restenose
US6156789A (en) * 1998-03-17 2000-12-05 Rhone-Poulenc Rorer S.A. Method for treating abnormal cell proliferation in the brain
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
EP1020188A1 (de) * 1999-01-13 2000-07-19 Aventis Pharma S.A. Neue Verwendung von Taxoid-Derivaten
US6362172B2 (en) * 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6649632B2 (en) 2000-02-02 2003-11-18 Fsu Research Foundation, Inc. C10 ester substituted taxanes
RU2264400C2 (ru) 2000-02-02 2005-11-20 Флорида Стейт Юниверсити Рисерч Фаундейшн, Инк. Таксан, фармацевтическая композиция на его основе и способ ингибирования роста опухоли
CN1362958A (zh) 2000-02-02 2002-08-07 佛罗里达州立大学研究基金有限公司 用作抗肿瘤剂的c7碳酸酯取代的紫杉烷
CA2410632A1 (en) 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
US6448401B1 (en) 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
EP1497275A4 (de) * 2002-04-05 2006-04-12 Natural Pharmaceuticals Inc Selektive acylierung sekundärer hydroxylgruppen
US7390898B2 (en) * 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
CA2494074A1 (en) 2002-08-02 2004-02-12 Immunogen, Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8703982B2 (en) 2003-03-17 2014-04-22 Phyton Holdings Llc Purification of taxanes
PE20050693A1 (es) 2004-02-13 2005-09-27 Univ Florida State Res Found Taxanos sustituidos con esteres de ciclopentilo en c10
WO2009145981A1 (en) 2008-03-31 2009-12-03 Florida State University Research Foundation, Inc. C(10) ethyl ester and c(10) cyclopropyl ester substituted taxanes
SI3351558T1 (sl) 2009-11-13 2020-07-31 Daiichi Sankyo Europe Gmbh Material in postopki za zdravljenje ali preprečevanje bolezni, povezanih s HER-3
EP2601220A2 (de) 2010-08-06 2013-06-12 U3 Pharma GmbH Verwendung von her3-bindemitteln in einer prostatabehandlung
CN103906758B (zh) * 2011-08-25 2017-05-10 株式会社博纳克 配糖体化合物、硫醚的制造方法、醚、醚的制造方法、配糖体化合物的制造方法及核酸的制造方法
CN104650012A (zh) 2013-11-22 2015-05-27 天士力控股集团有限公司 一种紫杉烷类化合物
US10377788B2 (en) 2015-04-02 2019-08-13 Bonac Corporation Method for producing glycoside compounds
CN110862410A (zh) * 2018-08-27 2020-03-06 深圳福山生物科技有限公司 三氟甲基硒化合物及其用途
EP3983370B1 (de) 2019-06-12 2023-08-02 Nouryon Chemicals International B.V. Verfahren zur herstellung von diacylperoxiden
HUE063679T2 (hu) 2019-06-12 2024-01-28 Nouryon Chemicals Int Bv Eljárás diacil-peroxidok elõállítására
US20220306490A1 (en) * 2019-06-12 2022-09-29 Nouryon Chemicals International B.V. Method for isolating carboxylic acid from an aqueous side stream

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678930B1 (fr) * 1991-07-10 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii.
FR2679230B1 (fr) * 1991-07-16 1993-11-19 Rhone Poulenc Rorer Sa Nouveaux derives d'analogues du taxol, leur preparation et les compositions qui les contiennent.
US5229526A (en) * 1991-09-23 1993-07-20 Florida State University Metal alkoxides
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
CA2111527C (en) * 1992-12-24 2000-07-18 Jerzy Golik Phosphonooxymethyl ethers of taxane derivatives

Also Published As

Publication number Publication date
NO943002D0 (no) 1994-08-15
CA2129288A1 (en) 1995-02-18
AU694941B2 (en) 1998-08-06
IL128425A0 (en) 2000-01-31
NO309093B1 (no) 2000-12-11
NO943002L (no) 1995-02-20
RU2128661C1 (ru) 1999-04-10
NZ264240A (en) 1997-10-24
CN1237580A (zh) 1999-12-08
ES2176212T3 (es) 2002-12-01
ATE217629T1 (de) 2002-06-15
IL110660A0 (en) 1994-11-11
DK0639577T3 (da) 2002-08-19
PT639577E (pt) 2002-10-31
DE69430611T2 (de) 2002-12-19
AU706511B2 (en) 1999-06-17
CN1111637A (zh) 1995-11-15
HUT67742A (en) 1995-04-28
CY2295B1 (en) 2003-07-04
FI943749A0 (fi) 1994-08-15
AU7026794A (en) 1995-03-02
EP0639577A1 (de) 1995-02-22
PL179636B1 (pl) 2000-10-31
JPH07149779A (ja) 1995-06-13
EP0639577B1 (de) 2002-05-15
RU94029662A (ru) 1996-07-10
KR100249306B1 (ko) 2000-04-01
KR950005834A (ko) 1995-03-20
HU9402342D0 (en) 1994-10-28
CN1100771C (zh) 2003-02-05
JP3062986B2 (ja) 2000-07-12
CZ194794A3 (en) 1995-08-16
CN1051315C (zh) 2000-04-12
PL304649A1 (en) 1995-02-20
FI113271B (fi) 2004-03-31
CA2129288C (en) 2000-05-16
FI943749A (fi) 1995-02-18
AU9135698A (en) 1999-01-14

Similar Documents

Publication Publication Date Title
DE69430611D1 (de) Phosphonooxymethyl oder Methylthiomethylether von Taxanderivaten als Antitumormittel
DE69328858D1 (de) Phosphonooxymethylether von Taxan-Derivaten
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
ATE267164T1 (de) 9-(substituiertes glycyl)amido-6-(substituiert)-5-hydroxy-6-deoxy etracycline
ES2161220T3 (es) 9-((glicil sustituido)amido)-6-desmetil-6-desoxitetraciclinas como agentes antibioticos.
LV12358A (lv) 7-(Aizvietoti)-9-(aizvietoti glicil)-amido-6-demetil-6-deoksitetraciklini
ATE231872T1 (de) Thiazolopyrimidinderivate
DK0705100T3 (da) Terapeutiske substituerede guanidiner
MX9601994A (es) Profarmacos de derivados de paclitaxel.
CA2152771A1 (en) 7-o-ethers of taxane derivatives
DK0681574T3 (da) C7-taxanderivater og farmaceutiske præparater, der indeholder disse
DK0577745T3 (da) Bis-naphtalimider indeholdende amid- og thioamid-forbindelsesstykker som anticancermidler.
DK1011329T3 (da) 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler
DK1108716T3 (da) C7-texanderivater og farmaceutiske præparater, der indeholder disse
ATE307577T1 (de) Pharmazeutische zusammensetzungen enthaltend neue iso-butenyl-substituierte taxane

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee